2016-2020年美国儿童碳青霉烯耐药与超广谱β-内酰胺酶肠杆菌目细菌感染
2019–2020年在美国6个站点研究儿童碳青霉烯耐药肠杆菌目(CRE)和超广谱β-内酰胺酶肠杆菌目(ESBL-E)感染。159例CRE中82.4%来自尿、12.6%来自血,年发病率0.47–0.87/10万;207例ESBL-E中94.7%来自尿、3.9%来自血,2019年发病率26.5、2020年19.63/10万。婴儿发病率高于其他年龄组2倍以上,CRE多为医疗相关社区起病,ESBL-E多为社区相关,需覆盖儿科和门诊的防控项目。
要点
- 儿童CRE年发病率0.47–0.87/10万,ESBL-E 2019年26.5、2020年19.63/10万。
- 婴儿CRE和ESBL-E发病率比其他年龄组高2倍以上。
- CRE 43.0%为医疗相关社区起病,ESBL-E 64.5%为社区相关。
核心结论
- 检测、预防和治疗多重耐药感染的项目必须包括儿科人群(尤其是年龄最小者)和门诊环境。
研究设计与样本
- 2019–2020年在美国6个站点对儿童碳青霉烯耐药肠杆菌目(CRE)和超广谱β-内酰胺酶肠杆菌目(ESBL-E)病例进行监测。
主要发现
- 159例CRE儿童(中位年龄5岁)中,131例(82.4%)从尿分离,20例(12.6%)从血分离,年发病率0.47–0.87/10万。
- 207例ESBL-E儿童(中位年龄6岁)中,196例(94.7%)从尿分离,8例(3.9%)从血分离,年发病率2019年26.5、2020年19.63/10万。
- 婴儿CRE和ESBL-E发病率比其他年龄组高2倍以上。
- CRE中医疗相关社区起病68例(43.0%)、社区相关43例(27.2%);ESBL-E中医疗相关社区起病40例(23.7%)、社区相关109例(64.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
2019–2020 at 6 US sites. Among 159 CRE cases in children (median age 5 years), CRE was isolated from urine for 131 (82.4%) and blood from 20 (12.6%). Annual CRE incidence rate (cases/100,000 population) was 0.47–0.87. Among 207 ESBL-E cases in children (median age 6 years), ESBL-E was isolated from urine of 196 (94.7%) and blood of 8 (3.9%). Annual ESBL-E incidence rate was 26.5 in 2019 and 19.63 in 2020. CRE and ESBL-E rates were >2-fold higher among infants than other age groups. Most CRE and ESBL-E cases were healthcare-associated community-onset (68 [43.0%] for CRE vs. 40 [23.7%] for ESBL-E) or community-associated (43 [27.2%] for CRE vs. 109 [64.5%] for ESBL-E). Programs to detect, prevent, and treat multidrug-resistant infections must include pediatric populations (particularly the youngest) and outpatient settings.
引用
- Grome HN, Grass JE, Duffy N, et al. Carbapenem-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacterales in Children, United States, 2016-2020. Emerg Infect Dis. 2024. PMID: 38781979. doi:10.3201/eid3006.231734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。